These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25366143)

  • 21. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
    Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
    J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.
    Marxer M; Ma HT; Man WY; Poon RY
    Oncogene; 2014 Jul; 33(27):3550-60. PubMed ID: 23955083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
    Shaikh MH; Idris A; Johnson NW; Fallaha S; Clarke DTW; Martin D; Morgan IM; Gabrielli B; McMillan NAJ
    Oral Oncol; 2018 Nov; 86():105-112. PubMed ID: 30409290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
    Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
    Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aurkin-A, a TPX2-Aurora A small molecule inhibitor disrupts Alisertib-induced polyploidy in aggressive diffuse large B cell lymphoma.
    Conway PJ; De La Peña Avalos B; Dao J; Montagnino S; Kovalskyy D; Dray E; Mahadevan D
    Neoplasia; 2024 Sep; 55():101014. PubMed ID: 38875929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
    Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
    Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
    Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.
    Iankov ID; Kurokawa CB; D'Assoro AB; Ingle JN; Domingo-Musibay E; Allen C; Crosby CM; Nair AA; Liu MC; Aderca I; Federspiel MJ; Galanis E
    Cancer Gene Ther; 2015 Sep; 22(9):438-44. PubMed ID: 26272026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
    Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
    Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.
    Liu Y; Hawkins OE; Su Y; Vilgelm AE; Sobolik T; Thu YM; Kantrow S; Splittgerber RC; Short S; Amiri KI; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    EMBO Mol Med; 2013 Jan; 5(1):149-66. PubMed ID: 23180582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
    Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC
    Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alisertib induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells.
    Fu Y; Zhang Y; Gao M; Quan L; Gui R; Liu J
    Mol Med Rep; 2016 Jul; 14(1):394-8. PubMed ID: 27177156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.
    Zhang Y; Ma Y; Wang Y; Mukhopadhyay D; Bi Y; Ji B
    Pancreatology; 2022 Jun; 22(5):619-625. PubMed ID: 35550115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.
    Zumbar CT; Usubalieva A; King PD; Li X; Mifsud CS; Dalton HM; Sak M; Urio S; Bryant WM; McElroy JP; Farmer G; Lehman NL
    J Neurooncol; 2018 May; 137(3):481-492. PubMed ID: 29396807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
    Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
    Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
    [No Abstract]   [Full Text] [Related]  

  • 38. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.
    Qi W; Spier C; Liu X; Agarwal A; Cooke LS; Persky DO; Chen D; Miller TP; Mahadevan D
    Leuk Res; 2013 Apr; 37(4):434-9. PubMed ID: 23153524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
    Wang L; Arras J; Katsha A; Hamdan S; Belkhiri A; Ecsedy J; El-Rifai W
    Mol Oncol; 2017 Aug; 11(8):981-995. PubMed ID: 28417568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.